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György Jermendy*Abstract
Based on the results of recent randomized, controlled clinical trials and analyses of their follow-up periods the
concept of metabolic memory cannot be restricted to antihyperglycaemic treatment only, rather it can be extended
to lipid-lowering and antihypertensive treatment and even life-style modification. This broadened concept can be
designated as vascular memory. According to this new concept, not only immediate and short-term but long-term
effects of the metabolic and cardiovascular risk milieu are of great importance. Consequently, early and intensive
lifestyle interventions, treatment of hyperglycaemia, lipid abnormalities and hypertension can result in beneficial
effects on cardiovascular outcomes even in the long run. On the contrary, failing in target-oriented treatment from
early detection of abnormalities can be associated with life-threatening cardiovascular events subsequently.
Additional experimental studies are needed to characterize the exact pathomechanism of vascular memory and
further clinical trials are also essential to explore its real clinical significance.
Keywords: Metabolic memory, Metabolic legacy, Vascular memory, Cardiovascular diseasesThe concept of metabolic memory was first described
among patients with type 1 diabetes in 2005, based on the
results of the follow-up observation of the original cohort
in the DCCT [1]. Although this term was already used in
former experimental diabetes models and studies with iso-
lated cells as early as the mid-1980s [2], the modern con-
cept of metabolic memory emerged from the DCCT-EDIC.
Reassuringly, late effect of previous antihyperglycaemic
treatment was documented among patients with type 2
diabetes during the follow-up of the original cohort in the
UKPDS [3]. The phenomenon was designated as metabolic
legacy. Based on the results of recent randomized, con-
trolled clinical trials and analyses of their follow-up periods
it became obvious that the concept of metabolic memory
cannot be restricted to antihyperglycaemic treatment only.
In this paper, clinical evidence concerning the late effect
of antihyperglycaemic treatment is summarized. Addition-
ally, the late effects of lipid-lowering and antihypertensive
treatment as well as life-style modification are also
reviewed. Taken together, results from recent clinical trials
suggest that the original concept of metabolic memory can
be defined in a much broader context.Correspondence: gyjermendy@mail.datanet.hu
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reproduction in any medium, provided the orAntihyperglycaemic treatment and its late effect
in type 1 diabetes
The DCCT was a multicenter, randomized, controlled
clinical trial which compared intensive insulin therapy with
conventional insulin regimens in patients with type 1 dia-
betes [4]. Originally, 1441 patients with type 1 diabetes
were randomly assigned to either intensive or conventional
insulin therapy and were followed for a mean of 6.5 years
between 1983 and 1993. A significant difference in HbA1c
values of the groups was found (mean values in patients
with intensive treatment 7.4 % and that in patients with
conventional treatment 9.0 %, p< 0.001). The risk of
both development and progression of microvascular
complications was significantly reduced by intensive in-
sulin treatment. Nevertheless, due to the low incidence
of cardiovascular events only a decreasing trend in risk
of macrovascular complications was observed during
the trial. The EDIC trial was a longitudinal observational
study involving the cohort from the DCCT. The goal of
this observational prospective evaluation was to assess
the long-term effects of differences in prior treatment
(intensive versus conventional insulin therapy during
the DCCT) on the late development and progression of
microvascular and macrovascular complications [5]. Al-
though the absolute difference in HbA1c values between. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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study, a consistent salutary effect of intensive insulin ther-
apy was observed. Namely, by achieving glucose control as
close to the nondiabetic range as safely possible, the risk of
development and progression of micro- and macrovascular
late complications was significantly reduced.
As for microvascular complications, the risk of retinop-
athy remained significantly reduced in the former group
with intensive insulin treatment 4 years after completion of
the original trial [6]. In addition, after 10 years in the
DCCIT/EDIC follow up the rates of retinopathy proved to
be lower than in the former group with conventional insu-
lin treatment despite the converged HbA1c levels during
the follow-up [7]. As for diabetic nephropathy, a reduction
of microalbuminuria and clinical albuminuria was observed
at 8 years of the follow-up. In addition, fewer cases with
hypertension and transplantation due to diabetic nephro-
pathy were recorded [8]. At a median follow-up of 13 years
after persistent microalbuminuria, former intensive dia-
betes therapy proved to be associated with improved renal
outcomes such as progression to microalbuminuria,
impaired glomerular filtration rate, end-stage renal disease
and regression to normoalbuminuria [9]. Over a median
follow-up period of 22 years in the combined study (at a
median follow-up of 16 years in the EDIC study) impair-
ment of the glomerular filtration rate (GFR) developed in
24 participants assigned to intensive therapy and in 46
assigned to conventional therapy resulting in a 50 % risk re-
duction with intensive therapy (95 % CI 18-69; p= 0.0006)
[10]. As for neuropathy, signs of both somatic and auto-
nomic neuropathy were less frequently observed in patients
with early intensive glycaemic control in the DCCT/EDIC
follow-up at 8 years [11]. Moreover, the benefits of former
intensive insulin treatment persisted for 13-14 years after
the DCCTcloseout and provide evidence of a durable effect
of prior intensive treatment on both peripheral [12] and
autonomic neuropathy [13].
As for cardiovascular complications, a beneficial effect of
early intensive glycaemic control on surrogate endpoints
such as progression of carotid intima-media thickness
[14,15] or coronary artery calcification [16] was also shown
during the EDIC follow-up at 6 and at 7-9 years, respect-
ively. A beneficial effect on cardiovascular events was also
documented [1]. Namely, during the mean 17 years of fol-
low-up, 46 cardiovascular events occurred in 31 patients
who had received intensive treatment in the DCCT, as
compared with 98 events in 52 patients who had received
conventional treatment. Intensive treatment reduced the
risk of any cardiovascular disease event by 42 % (95 % CI 9
to 63 %; p = 0.02) and the risk of nonfatal myocardial in-
farction, stroke, or death from cardiovascular disease by
57 % (95 % CI 12 to 79 %; p = 0.02).
Taken together, the DCCT/EDIC study demonstrated
that an average period of 6.5 years of intensive insulintreatment had a long-term, sustained effect on the subse-
quent risk of late micro- and macrovascular complica-
tions (Figure 1). This phenomenon was designated by
the authors as „metabolic memory” in 2005 [1].
Antihyperglycaemic treatment and its late effect
in type 2 diabetes
The UKPDS, one of the largest randomised clinical trials
in diabetology, embracing 20 years of study (1977-1997)
followed by a further 10 years of post-trial monitoring, has
radically altered our knowledge about the natural course
and treatment of type 2 diabetes. The original trial with
4209 randomized patients documented that intensive glu-
cose therapy versus conventional treatment (i.e. better
glycaemic control) was associated with a reduced risk of
clinically evident microvascular complications and a
nonsignificant reduction in the relative risk of myocar-
dial infarction in patients with newly diagnosed type 2
diabetes mellitus [17]. In the post-trial monitoring, 3277
patients were asked to attend annual UKPDS clinics for
5 years and later questionnaires were used to follow
patients in years 6 to 10. Between-group differences in gly-
cated hemoglobin levels were lost after at the first year
after closeout. In the sulfonylurea/insulin group, relative
reductions in risk persisted at 10 years for any diabetes-
related end point and microvascular disease. In addition,
as more events occurred, risk reductions for myocardial
infarction and death from any cause emerged (Table 1).
Similarly, a continued benefit after metformin therapy was
also evident among overweight patients. In conclusion, a
beneficial effect of better glycaemic control due to inten-
sive treatment persisted over time despite the early loss of
within-trial differences in glycated hemoglobin levels be-
tween the intensive-therapy group and the conventional-
therapy group. The phenomenon was called as legacy ef-
fect of earlier glucose control [3].
Lipid lowering treatment with statins and its late
effect
The legacy effect of lipid lowering treatment was documen-
ted by extended follow-up investigations of randomized
controlled trials with statins (simvastatin, pravastatin, ator-
vastatin) supporting the idea of vascular memory.
The 4 S was one of the earliest randomized trials for
assessing the effect of simvastatin in the secondary preven-
tion of myocardial infarction [18]. The benefits of simvas-
tatin in reducing mortality and cardiovascular events were
clearly demonstrated in this study (median duration of fol-
low-up 5.4 years). After completion, patients were followed
for an additional 2 years (interim analysis), and later for
5 years during which open-label simvastatin treatment was
provided for all patients [19,20]. It was found that simvas-
tatin treatment for 5.4 years in a placebo-controlled trial,
followed by open-label statin therapy for 5 years, was
Figure 1 The design of the DCCT-EDIC study and the development of late complications (From Nat Rev Endocrinol 2010; 6:665–675,
with permission of the publisher [Nature Publishing Group]). RET: retinopathy, ALB: albuminuria, NEU: neuropathy, mALB: microalbuminuria,
HYP: hypertension, CVD: cardiovascular diseases.
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low-up compared with open-label statin therapy for the
past 5 years only. It is of note, that during the post-trial
period there were no differences in cardiovascular event
rates in those originally assigned simvastatin or placebo
but importantly, the survival benefit of patients allocated
simvastatin compared with those allocated placebo that
accrued during the double-blind trial period persisted dur-
ing follow-up.
In the HPS, the efficacy and safety of lowering LDL-
cholesterol with daily 40 mg simvastatin (versus placebo)
were investigated [21]. During the in-trial period (mean
follow-up 5.3 years), allocation to simvastatin yielded an
average reduction in LDL cholesterol of 1.0 mmol/l and
a proportional decrease in major vascular events of 23 %
(95 % CI 19–28; p< 0.0001). During the post-trial period
of 6.7 years (when statin use and lipid concentrations
were similar in both groups), no further significant
reductions were noted in either major vascular events
(risk ratio 0.95 [95 % CI 0.89-1.02]) or vascular mortality
(0.98 [95 % CI 0.90-1.07]). Nevertheless, the substantialTable 1 Legacy effect of earlier glucose control in the
UKPDS (randomized phase of the trial completed in 1997,
post-trial monitoring period [median 8.5 years]
completed in 2007)
Aggregate endpoint 1997 2007
RRR p value RRR p value
Any diabetes related endpoint 12 % 0.029 9 % 0.040
Microvascular disease 25 % 0.0099 24 % 0.001
Myocardial infarction 16 % 0.052 15 % 0.014
All-cause mortality 6 % 0.44 13 % 0.007
RRR relative risk reduction.reduction in vascular events among patients allocated
simvastatin compared with those allocated placebo that
was found in the randomized period of the trial persisted
during observational follow-up after closeout of the ori-
ginal trial [22].
The WOSCOPS was designed to determine whether
pravastatin in men with hypercholesterolaemia and no his-
tory of myocardial infarction reduced the combined inci-
dence of nonfatal myocardial infarction and death from
coronary heart disease [23]. After randomisation, patients
were treated with either pravastatin or placebo for an aver-
age follow-up period of 4.9 years. In the double-blind
phase of the trial, a 31 % relative risk reduction (p< 0.001)
of combined endpoint was observed. The results of the
long-term follow-up of the WOSCOPS were published
later [24]. In the 10-year-long observational period, pravas-
tatin was provided for all participants alive at the comple-
tion of the double blind phase. As for primary combined
endpoint, the relative risk reduction favouring pravastatin
was 18 % (p= 0.02) in the observational period while it was
27 % (p< 0.001) in the entire investigation (5 year double-
blind phase+ 10 year observational follow-up). Taken to-
gether, 5 years of treatment with pravastatin was associated
with a significant reduction in coronary events for a subse-
quent 10 years in men with hypercholesterolaemia but
without a history of myocardial infarction.
The LIPID trial was designed to evaluate the effect of
pravastatin (40 mg daily) versus placebo in 9014 patients
(age 31-75 years) with a history of myocardial infarction or
hospitalization for unstable angina and initial plasma total
cholesterol levels of 4.0 – 7.0 mmol/l [25]. The mean fol-
low-up was 6.0 years. The relative risk reduction of death
from coronary heart disease favouring pravastatin was
24 % (p< 0.001). After closing the double blind phase, the
Figure 3 Kaplan-Meier estimates illustrating the primary
outcome (death from coronary artery disease [%]) in the LIPID
trial. In the double blind phase of the trial (mean duration: 6.0 years)
a clear difference between pravastatin and placebo occurred which
was maintained in the open, post-trial observational follow-up
period (duration: 2.0 years) (From Lancet 2002; 359: 1379–1387, with
permission).
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this observational period, pravastatin was provided for par-
ticipants treated formerly with placebo. In this period, no
difference in plasma LDL-cholesterol values of the two
groups was observed (Figure 2). Nevertheless, Kaplan-
Meier curves of cardiovascular events and total mortality
continuously diverged favouring the originally active versus
control arms despite conversion of curves representing the
changes of LDL-cholesterol values over time (Figure 3).
The ASCOT-LLA was a placebo-controlled randomized
trial for evaluating the effects of atorvastatin 10 mg daily
in the primary prevention of coronary heart disease in
hypertensive subjects who had a total cholesterol level of
≤6.5 mmol/l. The trial was stopped prematurely after a
median 3.3-year follow-up due to substantial benefits of
atorvastatin (36 % relative risk reduction) on composite
primary endpoint of cardiovascular events [27]. The
results of extended observations 2.2 years after trial clos-
ure were published in 2008 [28] while those of the 11-year
follow-up became available in 2011 [29]. At 2.2 years
after the end of the ASCOT-LLA, the relative risk re-
duction in all endpoints remained essentially un-
changed, although extensive crossovers from and to
statin usage occurred. At 8 years after closure of
ASCOT-LLA, all-cause mortality remained significantly
lower in those originally assigned atorvastatin (HR 0.86,
95 % CI 0.76-0.98, p = 0.02). Cardiovascular deaths were
fewer, but not significant (HR 0.89, 95 % CI 0.72-1.11,
p = 0.32) and non-cardiovascular deaths were signifi-
cantly lower (HR 0.85, 95 % CI 0.73-0.99, p = 0.03) in
those formerly assigned atorvastatin attributed to a re-
duction in deaths due to infection and respiratory ill-
ness. The authors concluded that a legacy effect of those
originally assigned atorvastatin might contribute to
long-term benefits on all-cause mortality.Figure 2 LDL-cholesterol values (mean, 95 % confidence
interval) in the LIPID trial. A clear difference between pravastatin
and placebo was observed in the double blind, randomized phase of
the study (mean duration: 6 years) while the difference disappeared in
the open-label, observational, post-trial follow up (duration: 2 years).
(From Lancet 2002; 359:1379–1387, with permission).Treatment with antihypertensive drugs and its
late effect
The legacy effect of treatment with antihypertensive drugs
was observed in some randomized, controlled trials with
post-trial observational follow-up. Nevertheless, the bene-
ficial late effect of tighter antihypertensive control was not
observed in the UKPDS 10-year follow-up.
In the HOPE study, the effect of ramipril versus pla-
cebo was assessed in patients who were at high risk for
cardiovascular events but who did not have left ventricular
dysfunction or heart failure [30]. A total of 9297 patients
(age ≥55 years) were randomly assigned to receive ramipril
(10 mg once per day) or matching placebo for a mean of
4.5 years. The primary outcome was a composite of myo-
cardial infarction, stroke, or death from cardiovascular
causes. A total of 651 patients who were assigned to re-
ceive ramipril (14.0 percent) reached the primary end
point, as compared with 826 patients who were assigned
to receive placebo (17.8 percent) (relative risk 0.78; 95 %
confidence interval, 0.70 to 0.86; p< 0.001). The partici-
pants of the HOPE trial were followed up after terminating
the original double blind phase for an additional 2.6 years
in order to assess whether the benefits were maintained
after trial cessation. During the extended follow-up
(HOPE-TOO trial), in those who were event-free at the
end of the HOPE study, there was a trend toward a further
reduction in major cardiovascular events [31]. During the
entire 7.2 years of follow-up, there was a significant risk re-
duction with ramipril for the primary composite outcome
of myocardial infarction, stroke and cardiovascular death
(relative risk reduction 17 %, p = 0.0002) (Figure 4).
In the TRACE study, patients with myocardial infarc-
tion and left ventricular systolic dysfunction (ejection
Figure 4 Kaplan-Meier estimates of the composite outcome of
myocardial infarction, stroke, or cardiovascular death in the
ramipril group and the placebo group of the HOPE trial and its
extension (HOPE-TOO) (From Circulation 2005; 112:1339–1346,
with permission).
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trandolapril or placebo [32]. The follow-up was 24 to
50 months. The relative risk reduction of death in the
trandolapril versus placebo group was 22 % (p = 0.001).
The long-term benefit of trandolapril was evaluated over
10-12 years of follow-up [33]. In the post-treatment
period no difference was observed between groups (rela-
tive risk 1.03, p = 0.75) regarding all-cause mortality but
for the entire follow-up, trandolapril significantly
reduced the risk of death compared with placebo (rela-
tive risk reduction 11 %, p = 0.031). The authors con-
cluded that in patients with left ventricular dysfunction,
trandolapril given shortly after a myocardial infarction
for 2–4 years has long-term benefits on mortality main-
tained for at least 10–12 years.
In the SOLVD trial, enalapril versus placebo was added
to conventional therapy in patients with reduced (≤35 %)
ejection fraction and a significant reduction in the inci-
dence of heart failure and the rate of related hospitaliza-
tions was observed in a median duration of 37.4 months.
In addition, there was a trend toward fewer deaths due to
cardiovascular causes among the patients who received
enalapril [34]. In order to establish whether the mortality
reduction with enalapril was sustained, subsequent vital
status was ascertained in 5165 individuals who were alive
when the trial had been completed. The duration of the
total follow-up was 12.1 years [35]. Beyond the original
trial period, the survival curves continued to diverge in
favour of the enalapril group for about 5 years, after which
the curves started to converge. The authors concluded
that the benefits of enalapril treatment continued to ac-
crue beyond the end of the trial resulting in a sustained
improvement in survival.
In the SYST-EUR study, elderly patients with isolated
systolic hypertension after 2 years of randomizedtreatment with nitrendipine or placebo were followed for
an additional 4 years with open-label antihypertensive
treatment [36]. Patients who received early antihyperten-
sive treatment, as compared with patients who initially
received placebo, had a significantly greater reduction in
the risk of stroke (28 %), cardiovascular complications
(15 %) and total mortality (13 %). The benefits were even
more pronounced in diabetic patients.
In the UKPDS with newly diagnosed type 2 diabetic
patients, the effect of tight blood pressure control was
also evaluated and, therefore, over a 4-year period 1148
patients with hypertension were randomized to tight or
less-tight blood-pressure control regimens. Tight control
was achieved by using ACE-inhibitor (captopril) or beta-
blocker (atenolol) while less-tight control was main-
tained by antihypertensive treatment that excluded these
agents. In the randomized trial, for tight as compared
with the less-tight control of blood pressure, there were
relative risk reductions of 24 % for any diabetes-related
endpoint, 32 % for diabetes-related death, 44 % for
stroke, and 37 % for microvascular disease [37]. During
the 10-year post-interventional period, differences in blood
pressure between the two groups during the trial disap-
peared within 2 years after termination of the trial and the
benefits of previously improved blood pressure control
were not sustained when between-group differences in
blood pressure were lost [38].
Lifestyle modification and its late effect
In the FDPS, 522 middle-aged, overweight subjects with
impaired glucose tolerance were randomly assigned to
either the intervention or the control group [39]. Each
subject in the intervention group received individualized
counselling aimed at reducing weight, total intake of fat,
and intake of saturated fat and increasing intake of fiber
and physical activity. The primary end point was the de-
velopment of type 2 diabetes, the duration of follow-up
was 3.2 years. The cumulative incidence of diabetes after
four years was 11 % in the intervention group and 23 %
in the control group. Overall, the risk of diabetes was
58 % lower (p< 0.001) in the intervention group than in
the control group. After the active intervention period,
participants who were still free of diabetes were further
followed-up for a median of 3 years [40]. Beneficial
changes achieved by participants in the intervention
group were maintained after discontinuation of the inter-
vention, and the corresponding incidence rates during
the post-intervention follow-up were 4.6 and 7.2 per 100
person-years (p = 0.0401), indicating 36 % reduction in
relative risk. Nevertheless, the active intervention period
did not decrease the risk of cardiovascular morbidity and
mortality during the first 10 years of follow-up [41].
In the China Da Qing Diabetes Prevention Study, 577
adult subjects with impaired glucose tolerance were
Figure 5 Cumulative incidence of cardiovascular events
(including death from cardiovascular causes, nonfatal stroke,
nonfatal myocardial infarction, coronary-artery bypass grafting,
percutaneous coronary intervention, revascularization for
peripheral atherosclerotic artery disease, and amputation) during
the entire Steno-2 study (7.8 years of randomized, controlled trial
and 5.5 years of open-label observational follow-up (From N Engl
J Med 2008; 358:580–591, with permission).
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style intervention groups (diet, exercise, or both). Active
intervention took place between 1986 and 1992 [42]. In
1992, after a 6-year intervention, participants were
informed of the final results and asked to continue with
normal medical care. In 2006, study participants were
followed-up to assess the long-term effect of intervention
[43]. Compared with control participants, those in the
combined lifestyle intervention groups had a 51 % lower
incidence of diabetes (hazard ratio 0.49; 95 % CI 0.33 -
0.73) during the active intervention period and a 43 %
lower incidence (hazard ratio 0.57; 95 % CI 0.41 - 0.81)
over the 20 year period.
In the 2.8 years of the DPP randomised clinical trial, dia-
betes incidence in high-risk adults was reduced by 58 %
with intensive lifestyle intervention and by 31 % with met-
formin, compared with placebo [44]. During the 10-year
follow-up since randomisation, incidences in the former
placebo and metformin groups fell to equal those in the
former lifestyle group, but the cumulative incidence of dia-
betes remained lowest in the lifestyle group. Accordingly,
prevention or delay of diabetes with lifestyle intervention
or metformin persisted for at least 10 years [45].
Multifactorial intervention and its late effect
The STENO-2 study, conducted over 7.8 years, recog-
nized that the risk of cardiovascular events and death
could be halved among patients with longstanding dia-
betes and microalbuminuria by intensive multifactorial
treatment [46]. Patients from this cohort were subse-
quently followed for a mean of 5.5 years and results from
this post-trial observation documented that intensive
intervention had sustained beneficial effects with respect
to vascular complications and death (Figure 5) [47].
Possible pathomechanism
Although the exact pathomechanism of vascular memory
is not clearly understood some elements of the patho-
physiologic process have already been highlighted by ex-
perimental studies. Furthermore, explanations of the late
effect of an earlier treatment have become available from
clinical studies.
As for antihyperglycaemic treatment, increased forma-
tion of AGE could be a plausible cause of structural and
functional changes occurring in the early metabolic en-
vironment but carrying implications for developing and
progressing micro- and macrovascular complications in
the long run [48-50]. In addition, altered mitochondrial
function due to oxidative stress should also be considered
[51]. Recently, increasing evidence suggests that epigenetic
factors play a key role in the complex interplay between
genes and the environment [52]. Thus, sustained hypergly-
caemia can lead via methylation or histone acetylation to
dysregulated epigenetic mechanisms that affect chromatinstructure and gene expression [53-57]. Accordingly, the
altered state of the epigenome might be the underlying
mechanism contributing to the metabolic memory result-
ing in micro- and macrovascular dysfunction in diabetes
even after achieving adequate glycaemic control. Neverthe-
less, it was found in a further experimental study that ex-
posure to oscillating glucose was more deleterious than
constant high glucose and induced a metabolic memory
after glucose normalisation [58]. In clinical circumstances,
the role of AGE formation was suggested as a rational
basis for the phenomenon of metabolic memory in the
DCCT cohort [59]. However, some other elements should
also be considered. For example microalbuminuria, a well
characterized cardiovascular risk factor, was less pro-
nounced in the intensively treated subgroup during the en-
tire DCCT-EDIC observation which could contribute to
the more favourable cardiovascular outcome when sub-
groups with former intensive versus conventional treat-
ment were compared [9]. Interestingly enough, re-
analyzing the DCCT with respect to time-dependent
memory effects of HbA1c revealed that the most current
(in real time) HbA1c value was not the most important,
but values from 2 to 3 years prior contributed the greatest
risk to current progression of retinopathy [60]. Recently,
links between microvascular dysfunction and subsequent
macrovascular disease were supposed and microvascular
structural changes were suggested to play a potential role
in the metabolic memory [61].
Although late beneficial effect of early therapy with
statins was documented in several lipid trials, the pato-
mechanism remains obscure. Although the time of initi-
ating treatment with statins and the dose of the
respective statin are of great importance, the non-lipid
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Generally, statins are linked to the inhibition of HMG-
CoA reductase and a subsequent reduction in synthesis of
isoprenoid intermediates by which a number of critical
intracellular signalling processes are prevented leading to
beneficial effect on subclinical inflammation and endothe-
lial function. All these factors may have a role in vascular
protection with statin therapy even long term [62,63].
As for treatment with antihypertensive drugs, it should
be emphasized that no legacy effect in the UKPDS follow-
up was observed [38]. Nevertheless, the absence of the leg-
acy effect in the UKPDS hypertension sub-study is heavily
debated [64]. It is of note that drugs (captopril or ateno-
lol) used for achieving tight blood pressure control in
this sub-study are not really used for long-term blood
pressure control in current practice. In addition, the target
blood pressure values in the UKPDS were far from those
recommended in current guidelines [65]. The sub-study
was not really powered to detect the late effect of antihy-
pertensive treatment and the higher HbA1c values in the
tight control group might mask the potential benefits
during the follow-up. Consequently, no final conclusion
can be drawn from the UKPDS hypertension sub-study
regarding a legacy effect of antihypertensive treatment.
It is of note, however, that results of other clinical trials
with antihypertensive drugs (HOPE, TRACE, SOLVD)
should be considered supportive for a legacy effect. In
this respect it should be noted that RAAS dysregulation
is heavily involved in triggering organ damage in
patients with diabetes. Hyperglycaemia directly upregu-
lates intracellular synthesis of angiotensin-II and high
glucose stimulates angiotensinogen gene expression and
cell hypertrophy. Ultimately, angiotensin-II activation
leads to pathologic vessel remodelling [66]. In light of
these observations, it seems obvious that blocking
RAAS and consequently, interfering pathways involved
in early organ damage may have late beneficial vascular
effect. Conversely, delayed versus immediate start of
antihypertensive treatment may have a deleterious effect
on cardiovascular outcome [67].
Regarding life-style modification it is of great import-
ance that weight reduction can result in improvement in
both insulin resistance and beta-cell function. Accord-
ingly, the incidence rate of diabetes mellitus in subjects
originally recruited with impaired glucose tolerance
proved to be lower in the intervention versus control
groups during the randomized trial and even the post-
trial period [68]. In this respect it is of note that some
differences in patients’ weight between groups were
maintained during the follow-up period of the FDPS
[69]. Notably, results from studies with life-style modifi-
cation indicated that incidence of type 2 diabetes rather
than that of cardiovascular events decreased during the
entire observation [41,43,45].Summary and practical consequences of the
vascular memory
It is very likely that the term of metabolic memory
observed in type 1 and type 2 diabetic patients with dif-
ferent antihyperglycaemic treatment [70,71] can be
extended to antihypertensive and lipid-lowering treat-
ment and even life-style modification. This broadened
concept can be designated as vascular memory. Some
years ago this broadened concept was considered as a
hypothesis [72] but with more convincing follow-up data
from recent randomized clinical trials it appears very
likely that this phenomenon really exists.
According to the concept of the vascular memory, not
only immediate and short-term but even long-term
effects of the metabolic and cardiovascular risk milieu
could be expected. Consequently, early and intensive
treatment of hyperglycaemia, lipid abnormalities, and
hypertension can result in beneficial effects on cardiovas-
cular outcomes even in the long run (“good memory”).
On the contrary, failing in target-oriented treatment from
early detection of abnormalities can be associated with
subsequent life-threatening cardiovascular events (“bad
memory”) [73]. Similarly, late beneficial effect of life-style
modification (versus regular care) on the incidence of type
2 diabetes was observed among subjects with impaired
glucose tolerance. Importantly, ADDITION-Europe is the
only randomized trial so far aiming to assess the effect of
early intensive intervention of screen-detected patients
with type 2 diabetes [74]. At the end of the 5-year pro-
spective study a small, non-significant reduction in the in-
cidence of cardiovascular events and death was observed.
Taken together, the “memory effect” is a new challenge
for treatment aiming to reduce cardiometabolic risks and
events. It is obvious that not only experimental studies
but further clinical trials are needed to explore the exact
pathomechanism and the particular clinical significance
of the vascular memory.
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